Seventh Sense Biosystems appoints Weisman as president and CEO

Thursday, June 14, 2012 12:21 PM

Seventh Sense Biosystems, a Cambridge, Mass.-based privately-held medical device company developing the novel Touch Activated Phlebotomy (TAP) painless blood sampling system, has appointed Howard Weisman as president, CEO and board member.  

Weisman comes to Seventh Sense with experience launching medical products, most recently as the founder, chairman, and CEO of EKR Therapeutics, which announced its sale to Cornerstone Therapeutics in May 2012.  Prior to his role at EKR, Weisman co-founded ESP Pharma, serving as its president and COO from its initial funding in 2001 through to its sale to PDL BioPharma in 2005 for over $500 million.  He began his career in sales and marketing at Merck and later joined Parke Davis, a division of Warner Lambert, to oversee the launch of its diabetes franchise in 1995.

The company also announced that it has closed the final tranche of a $10 million series A financing with existing investors Flagship Ventures and Polaris Venture Partners.  The company will use this financing to complete clinical testing and to commercialize its first TAP-based blood collection device for point of care diagnostics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs